Natera Presents Promising Results for Signatera™

Natera, a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, has presented data that validates the ability of Signatera™ to monitor treatment response, detect minimal residual disease, and identify disease recurrence in bladder and colorectal cancers at the AACR Annual Meeting in Chicago, April 14-18, 2018.

"Having replicated our outstanding performance across lung cancer, bladder cancer, and colon cancer, we believe that Signatera is showing promise as a pan-cancer platform," said Jimmy Lin, M.D., Ph.D., MHS, Natera's Chief Scientific Officer, Oncology. "We look forward to Signatera's use in clinical trials, for patient selection and treatment response evaluation in the adjuvant, neoadjuvant and metastatic settings."

Three posters were presented at the AACR Annual Meeting:

• April 16, 2018, 8:00 a.m.–12:00 p.m., Section 26: Personalized circulating tumor DNA analysis to monitor colorectal cancer.
• April 17, 2018, 8:00 a.m.–12:00 p.m., Section 27: Sequencing of plasma of cfDNA from patients with locally advanced bladder cancer for surveillance and therapeutic efficacy monitoring.
• April 17, 2018, 1:00–5:00 p.m., Section 24: Analytical validation of the Signatera RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay.

Natera also hosted an Exhibitor Spotlight Theatre on Sunday, April 15 at 1:30 p.m., titled "Clonal ctDNA Monitoring Using Signatera (RUO) Platform: Pan-Cancer Applications for Biopharmaceutical Research."

Receive the latest news on the upcoming events. Become a free member today.